ES2176776T3 - Ligandos del neuropeptido-y. - Google Patents
Ligandos del neuropeptido-y.Info
- Publication number
- ES2176776T3 ES2176776T3 ES97939524T ES97939524T ES2176776T3 ES 2176776 T3 ES2176776 T3 ES 2176776T3 ES 97939524 T ES97939524 T ES 97939524T ES 97939524 T ES97939524 T ES 97939524T ES 2176776 T3 ES2176776 T3 ES 2176776T3
- Authority
- ES
- Spain
- Prior art keywords
- neuropeptide
- ligands
- neuropeptide ligands
- formula
- agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 101710151321 Melanostatin Proteins 0.000 abstract 2
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
Abstract
Compuesto de fórmula en donde A es O, S, o N-R, en donde R es un alquilo de cadena corta (C1-C8); D es O, S o N-R7; W es N, CH o C-R8; R1 y R3 son independientemente H, radicales alquilo de C1-C14, lineales o ramificados, cíclicos o acíclicos, saturados o insaturados, opcionalmente substituidos por grupos hidroxi, oxialquilo de cadena corta, tioalquilo, oxiarilo o tioarilo, en donde dichos grupos que soportan arilos son substituidos opcionalmente por grupos halógeno, oxialquilo de cadena corta, tioalquilo, alquilo de cadena corta, trifluorometoxi, trifluoroetoxi o trifluorometilo, y opcionalmente dichos grupos alquilo están substituidos por estructuras cíclicas seleccionadas del grupo que consta de anillos que tienen un tamaño de anillo de entre 3 y 10 átomos, o dichos grupos alquilo están substituidos por partes aromáticas o heteroaromáticas, conteniendo opcionalmente dichos grupos arilo o heteroarilo substituyentes en el anillo arílico seleccionado del grupo consistente en grupos alquilode cadena corta, oxialquilo, amino, aminoalquilo de cadena corta, aminoacilo de cadena corta, halógenos, y trifluo rometilo o trifluorometoxi; R2 es en donde W2 es C=O, SO2, C(O)NH; SO; o está ausente; Q es (a) un (-CH2-)z substituido o no substituido, en donde z=1 a 12, y cuando -CH2- está subs tituido, los grupos substituyentes son alquilo de cadena corta, arilo o heteroarilo; y cuando z>1, al menos un grupo -CH2- está reemplazado opcionalmente por un heteroátomo seleccionado del grupo consis tente en O, S o un N substituido o no substituido, en donde la parte substituyente se selecciona del grupo consistente en alquilo de cadena corta, arilo, heteroarilalquilo e hidrógeno; (b) un anillo carbocíclico o heterocíclico saturado de fórmula (-CH2-)x en donde l y m son de 0-5, y en donde x=3-12, preferiblemente de 3-8, y opcionalmente, uno o más grupos -CH2- se substituyen por un radical seleccionado del grupo consistente en alquilo de cadena corta saturado o insaturado, cicloalquilo, arilo y heteroarilo; y opcionalmente al menos uno de los grupos CH2- está reem plazado por un heteroátomo seleccionado del grupo consistente en O, S, Se y N substituido o no substituido, y cuando N está substituido, el grupo substituyente se selecciona del grupo consistente en alquilo de cadena corta, arilo, heteroarilo e hidrógeno; (c) un anillo aromático carbocíclico o heterocíclico de fórmula (-CH=CH-)y en donde l y m son de 0-5, y en donde y opcionalmente al menos uno de los grupos -CH- está substituido por X1, X2 o tanto X1 como X2 en donde X es cualquier substituyente cíclico, por ejemplo grupos alquilos saturados o insaturados, lineales o ramificados, grupos oxialquilos de cadena corta o halógenos, y opcionalmente, al menos uno de los grupos -CH- está reemplazado por N, o alternativamente, uno de los grupos -CH=CH- está reemplazado por un heteroátomo seleccionado del grupo consistente en O, S, Se y N-R11; también opcionalmente, al menos uno de los grupos -CH=CH- es una unión con la cual se puede fusionar otra estructura cíclica, bien saturada o bien insaturada, formando de esta manera sistemas aromáticos o heteroaromáticos condensados seleccionados, por ejemplo, del grupo consistente en clases de naftaleno, indole, benzofurano, quinolina, quinazolina y benzodioxano; X3 es un substituyente en Q el cual puede ser H, alquilo de cadena corta, arilo, oxialquilo de cadena corta, hidroxi, trifluorometilo, y substituyentes cíclicos similares y comunes. R4 se selecciona del grupo consistente en las siguientes fórmulas generales: en donde A1 es O, S, NH o N-alquilo de cadena corta o arilo; R5 a R9, R11 y R12 se seleccionan independientemente del grupo consistente en H, radicales alquilo de C1 a C14, lineales o ramificados, saturados o insaturados, cíclicos o acíclicos, substituidos o no substituidos, o radicales arilos o heteroarilos, y cuando cualquiera de los R5 a R9, R11 o R12 es un radical arilo o heteroarilo substituido, el grupo substituyente se selecciona de los miembros del grupoconsistente en halógeno, oxialquilo de cadena corta, tioalquilo, alquilo de cadena corta, trifluorometoxi y trifluorometilo, y cuando cualquiera de los R5 a R9, R11 o R12 es un radical alquilo substituido, la parte substituyente se selecciona del grupo consistente en sistemas cíclicos no aromáticos que tienen de 3 a 14 átomos de anillo, y sistemas aromáticos y heteroaromáticos y anillos heterocíclicos que tienen de 4- 12 miembros de anillo, y dichos anillos aromáticos y heteroaromáticos opcionalmente están substituidos por radicales seleccionados del grupo consistente en alquilo de cadena corta, oxialquilo, amino, aminoalquilo de cadena corta, amidoacilo de cadena corta, halógenos, perfluoroalquilo, y perfluoroalquilo de cadena corta; o R6 es H, alquilo de C1 a C14, lineal o ramificado, cíclico o acíclico, saturado o insaturado; arilo; heteroarilo; arilalquilo de cadena corta; heteroarilalquilo de cadena corta; arilalquilo de cadena corta condensado; heteroarilalquilo de cadena corta condensado; diarilalquilo de cadena corta; bisheteroarilalquilo de cadena corta; o heteroarilalquilarilo de cadena corta; o derivados parcial o totalmente saturados de los mismos; o R6 puede ser R6 el cual es R6-NH o R6-N-alquilo de cadena corta; R10 es hidrógeno, grupos alquilos de C1-C12, lineales o ramificados, saturados o insaturados, cíclicos o acíclicos, que contienen opcionalmente enlaces dobles o triples; un arilo, opcionalmente substituido con grupos tales como halógeno, alquilo de cadena corta, oxialquilo, aminoalquilo, dialquilaminoalquilo de cadena corta, hidroxi; arilalquilo; oxiarilalquilo; 2-tetrahidrofurfurilo; 3-tetrahidrofurfurilo; hidroxial quilo terminal con cadenas de hidrocarburo de C2-C10 y amidoalquilo tal como el 2-acetamidoetilo; o R9 y R10 pueden formar opcionalmente un anillo de 3 a 10 miembros; y los compuestos comprenden cualquier isómero ópticamente activo de los mismos en forma de isómeros ópticos separados, puros o parcialmente purificados o mezclas racémicas delos mismos; y las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2579196P | 1996-08-23 | 1996-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2176776T3 true ES2176776T3 (es) | 2002-12-01 |
Family
ID=21828075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97939524T Expired - Lifetime ES2176776T3 (es) | 1996-08-23 | 1997-08-22 | Ligandos del neuropeptido-y. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6849733B1 (es) |
| EP (1) | EP0984778B1 (es) |
| JP (1) | JP2001502296A (es) |
| AT (1) | ATE218859T1 (es) |
| AU (1) | AU4159297A (es) |
| CA (1) | CA2268051A1 (es) |
| DE (1) | DE69713402T2 (es) |
| DK (1) | DK0984778T3 (es) |
| ES (1) | ES2176776T3 (es) |
| PT (1) | PT984778E (es) |
| WO (1) | WO1998007420A1 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| SE9802206D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| SE9802207D0 (sv) | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| EP1033366A3 (en) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Amide derivatives useful as Neuropeptide Y (NPY) antagonists |
| US6355807B1 (en) | 1999-08-24 | 2002-03-12 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
| US6774243B2 (en) | 1999-08-24 | 2004-08-10 | Agouron Pharmaceuticals, Inc. | Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates |
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| MXPA03002594A (es) * | 2000-10-30 | 2003-06-30 | Warner Lambert Co | Ligandos de amidinourea del receptor de serotonina y composiciones, sus usos farmaceuticos y procedimientos para su sintesis. |
| ES2278016T3 (es) | 2001-04-09 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r). |
| PT1551834E (pt) | 2002-05-23 | 2010-09-30 | Novartis Vaccines & Diagnostic | Compostos de quinazolinona substituídos |
| WO2004098591A2 (en) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases |
| CA2523015A1 (en) | 2003-05-23 | 2004-12-29 | Chiron Corporation | Guanidino-substituted quinazolinone compounds as mc4-r agonists |
| AU2004290499C1 (en) | 2003-11-03 | 2011-02-24 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| MXPA06005736A (es) | 2003-11-19 | 2006-12-14 | Chiron Corp | Compuestos de quinazolinona con bioacumulacion reducida. |
| CA2554809C (en) | 2004-02-05 | 2014-04-29 | Probiodrug Ag | Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase |
| WO2006108218A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration |
| US7273882B2 (en) * | 2005-06-21 | 2007-09-25 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as β-secretase inhibitors |
| EP1945632B1 (en) | 2005-11-08 | 2013-09-18 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7657504B2 (en) * | 2006-10-10 | 2010-02-02 | Microsoft Corporation | User interface for displaying images of sights |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| EP2639224B1 (en) | 2007-12-07 | 2016-08-24 | Vertex Pharmaceuticals Incorporated | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| WO2013112804A1 (en) | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| JP6963896B2 (ja) | 2013-11-12 | 2021-11-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法 |
| PT3221692T (pt) | 2014-11-18 | 2021-09-10 | Vertex Pharma | Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência |
| WO2018097126A1 (ja) * | 2016-11-25 | 2018-05-31 | 日本曹達株式会社 | グアニジン化合物および殺菌剤 |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1983000624A1 (en) * | 1981-08-24 | 1983-03-03 | Chou, Billy, Ja-Ray | Promotion of feed efficiency in animals |
| US4486439A (en) * | 1981-08-24 | 1984-12-04 | William H. Rorer, Inc. | Treatment of coccidiosis |
| US5380945A (en) * | 1989-06-21 | 1995-01-10 | Abbott Laboratories | Guanidino compounds as regulators of nitric oxide synthase |
| DE59006842D1 (de) * | 1990-03-30 | 1994-09-22 | Heumann Pharma Gmbh & Co | Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung. |
| US5583238A (en) | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| US5482947A (en) * | 1990-11-19 | 1996-01-09 | Talley; John J. | Retroviral protease inhibitors |
| DE4301452A1 (de) * | 1993-01-20 | 1994-07-21 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| FR2701480B1 (fr) | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
| US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| EP0895781A3 (en) | 1994-10-20 | 1999-07-07 | Eli Lilly And Company | Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins |
| AU692977B2 (en) | 1994-11-07 | 1998-06-18 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
-
1997
- 1997-08-22 AU AU41592/97A patent/AU4159297A/en not_active Abandoned
- 1997-08-22 DK DK97939524T patent/DK0984778T3/da active
- 1997-08-22 CA CA002268051A patent/CA2268051A1/en not_active Abandoned
- 1997-08-22 PT PT97939524T patent/PT984778E/pt unknown
- 1997-08-22 US US08/916,527 patent/US6849733B1/en not_active Expired - Fee Related
- 1997-08-22 AT AT97939524T patent/ATE218859T1/de not_active IP Right Cessation
- 1997-08-22 ES ES97939524T patent/ES2176776T3/es not_active Expired - Lifetime
- 1997-08-22 JP JP10511019A patent/JP2001502296A/ja not_active Ceased
- 1997-08-22 EP EP97939524A patent/EP0984778B1/en not_active Expired - Lifetime
- 1997-08-22 DE DE69713402T patent/DE69713402T2/de not_active Expired - Fee Related
- 1997-08-22 WO PCT/US1997/014854 patent/WO1998007420A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PT984778E (pt) | 2002-09-30 |
| ATE218859T1 (de) | 2002-06-15 |
| EP0984778A4 (en) | 2000-06-07 |
| EP0984778A1 (en) | 2000-03-15 |
| JP2001502296A (ja) | 2001-02-20 |
| DE69713402T2 (de) | 2002-11-07 |
| DE69713402D1 (de) | 2002-07-18 |
| EP0984778B1 (en) | 2002-06-12 |
| US6849733B1 (en) | 2005-02-01 |
| CA2268051A1 (en) | 1998-02-26 |
| WO1998007420A1 (en) | 1998-02-26 |
| DK0984778T3 (da) | 2002-09-16 |
| AU4159297A (en) | 1998-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2176776T3 (es) | Ligandos del neuropeptido-y. | |
| UY34152A (es) | ?oxazolidinonas substituidas y su uso?. | |
| DK1204654T3 (da) | Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister | |
| BR9808491A (pt) | Compostos calcilìticos | |
| EP0599532A3 (en) | One-component curable organosiloxane compositions. | |
| ATE228111T1 (de) | M-amidinophenyl-analoga als faktor-xa-inhibitoren | |
| SK86699A3 (en) | Nitrogen containing heteroaromatics as factor xa inhibitors | |
| IT1269176B (it) | Eterobicicli ad attivita' fungicida | |
| BG103310A (en) | Benzonaphthyridins as bronchial therapeutical means | |
| SE0004245D0 (sv) | Novel compounds and their use | |
| MY105344A (en) | New sulphonyl compounds | |
| SG52766A1 (en) | Organic compounds | |
| TR199903014T2 (xx) | 5-HT1F Agonistleri olarak yararl� karboksamitler. | |
| ATE245642T1 (de) | Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4 | |
| ES2178765T3 (es) | Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano. | |
| BG105539A (bg) | Елетриптан хидробромид монохидрат | |
| DK1204659T3 (da) | Serotonerge benzofuraner | |
| RU95106653A (ru) | Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе | |
| GB2324091A (en) | Metalloproteinase inhibitors | |
| ATE280169T1 (de) | Serotonerge benzothiophene | |
| EA199900534A1 (ru) | Имидазопиридазины | |
| YU48915B (sh) | Sulfonilkarbamid i postupak za njegovo dobijanje | |
| FR2693911B1 (fr) | Nouvelles utilisations d'un appareillage d'électro-anesthésie. | |
| TR200100133T2 (tr) | FKBP İnhibitörleri | |
| TR199701298T1 (xx) | Tetralinler. |